1. Home
  2. EVAX vs HBIO Comparison

EVAX vs HBIO Comparison

Compare EVAX & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evaxion Biotech

EVAX

Evaxion Biotech

HOLD

Current Price

$3.12

Market Cap

25.8M

Sector

Health Care

ML Signal

HOLD

Logo Harvard Bioscience Inc.

HBIO

Harvard Bioscience Inc.

HOLD

Current Price

$6.05

Market Cap

26.5M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVAX
HBIO
Founded
2008
1901
Country
Denmark
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
25.8M
26.5M
IPO Year
2020
2000

Fundamental Metrics

Financial Performance
Metric
EVAX
HBIO
Price
$3.12
$6.05
Analyst Decision
Strong Buy
Buy
Analyst Count
3
2
Target Price
$11.67
$18.00
AVG Volume (30 Days)
21.3K
12.7K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$116,176,000.00
Revenue This Year
N/A
$4.77
Revenue Next Year
$328.20
$8.55
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.45
$0.38
52 Week High
$12.15
$7.50

Technical Indicators

Market Signals
Indicator
EVAX
HBIO
Relative Strength Index (RSI) 44.53 46.12
Support Level $2.97 $5.91
Resistance Level $3.61 $6.70
Average True Range (ATR) 0.20 0.28
MACD 0.02 -0.04
Stochastic Oscillator 32.79 6.11

Price Performance

Historical Comparison
EVAX
HBIO

About EVAX Evaxion Biotech

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.

Share on Social Networks: